Cell and gene therapies are transforming medicine — from CAR-T in oncology to next-generation gene therapies targeting rare disease.

Ahead of the ARCS–DIA Cell & Gene Therapy Summit, Tim Boyle and Anna Megalakakis unpack Australia’s advanced therapies landscape. They explore manufacturing capability, workforce shortages, funding reform, regulatory pathways, and whether Australia can scale beyond clinical trials to become a regional CGT leader.

A practical, strategic discussion for regulators, industry professionals, scientists and clinical research leaders.

🎧 Listen now to understand where Australia stands — and what must happen next.